Well after all the earlier promises, now slightly overdue and the SMA chart starting to indicate a reversal of fortune I think you might be wise to buy some. Or if you hold some, top up as I've been doing lately.

For those not familiar with this stock check on previous news over the last year or so re 'promises'.

So they did:

Inyx Signs Deal with Plethora Solutions to Produce Novel HFA Aerosol Indicated for the Treatment of Premature Ejaculation for Clinical Trial in the United States




NEW YORK, Nov. 2 /PRNewswire-FirstCall/ -- Inyx, Inc. , a specialty pharmaceutical company focused on niche drug delivery technologies and products, announced today that it has signed an agreement with Plethora Solutions Holdings plc (AIM: PLE), an emerging U.K. specialty pharmaceutical company, to manufacture a topical HFA aerosol product used in the treatment of premature ejaculation (PE) for Phase III clinical trial in the United States. The production will be conducted at Inyx USA's FDA-approved site in Puerto Rico.

Jack Kachkar, M.D., Chairman and CEO of Inyx, Inc., said, "We are very pleased that Inyx has been selected for the production of Plethora's PE product for the Phase III clinical trial. We are particularly delighted that a U.K.-based company has selected Inyx USA. This collaboration reflects our expertise in HFA aerosol production and our overall capabilities on both sides of the Atlantic."

Dr. Steven Powell, CEO of Plethora, commented, "We are very happy with our collaboration with Inyx, which allows us to progress PSD502 down the path towards Phase III clinical development."

Plethora's PE product, known as PSD502, is a topical agent comprised of a unique proprietary and rapidly absorbed formulation of two well established local anesthetics, dispensed by a metered dose spray.

PE is a medically recognized condition defined as "persistent or recurrent ejaculation with minimal sexual stimulation before, upon or shortly after penetration, and before the person wishes it." PE is the most common form of sexual dysfunction in men. According to the American Medical Association, approximately 20 million men in the U.S. experience PE. Since there is currently no approved pharmaceutical therapy, the PE market offers significant potential for development and growth. An effective drug therapy for PE may have a commercial potential comparable to the erectile dysfunction drug, Viagra(R), for which current annual sales are approximately $1.7 billion.



Source: http://www.wivb.com/Global/story.asp?S=5625837

or just Google it.

Good find, Hondaman, thanks very much!

some more info showing confidence Plethora have signed a deal with Inyx for them to manufacture the aerosol for PSD502 for phase III trials for Plethora.
(http://www.inyxinc.com/page420618.aspx)

Just my feeling but I am going for a deal to be announced this month.
Lets see -good luck all!! although we have been informed by RNS that it will be in second half so not long to go anyways!

from recent results -this is the interesting part for me!
" In the second half of 2006 we look forward to the continued growth of product revenues and are confident that we will add significant licensing income from PSD502 to the top line.'

Timm Medical is bringing in great revenue going by the RNS and on top will be immediate licensing revenue from PSD502.

I am going to stick with next week as news week on deal news.
Good luck all!

News can still come November 2006 -still a few days to go -otherwise December 2006 it will defo come -company have stated this in the results RNS that PSD502 will bring in SIGNIFICANT licensing revenue in 2006 .

Honda, I too am hoping that news will soon be forthcoming, but predictions of when deals will be made can be very unreliable. I'm content to wait a while if necessary; happy to get in ahead of the herd.

soul -todays news is a start of more news -thats my take and PSD502 news this year 2006 will mean a great mark up so yes its best to get in before that happens.

These relatively minor items of news are good and lift the price steadily in prelude to major news. After all, doube 2 is better than double 1.50p :o)

Plethora Solutions - Product Update PSD401
RNS Number:7197M
Plethora Solutions Holdings PLC
27 November 2006


PLETHORA SOLUTIONS HOLDINGS PLC

Product Update

PSD401 - Sexual Activity Monitor (SAMTM)
Plethora Enters Into Agreement with Global Pharmaceutical Company

Plethora Solutions Holdings plc ('Plethora' or the 'Company', AIM : PLE), the
specialist developer of products for the treatment and management of urological
disorders, today announces that it has entered into an agreement with a major
multi-national pharmaceutical company to supply Plethora's Sexual Assessment
Monitor (SAMTM, PSD401), a device for the measurement and automated recording of
ejaculation time, into a clinical programme using time to ejaculation as a
primary endpoint. The use of PSD401 to measure time to ejaculation introduces a
new level of accuracy over the traditional method of measurement using a hand
held stop watch. A similar agreement was entered into with Johnson & Johnson in
2005.

Plethora recently published the successful conclusion of development trials on
PSD401. (Dinsmore et al (2006) BJU Int, 98; 613-61). These trials, monitoring
both healthy volunteers and patients suffering from Premature Ejaculation (PE),
established the reproducibility, efficacy and safety of the product and the
ability to discriminate between healthy patients with 'normal' latency times and
PE sufferers.

Dr. Mike Wyllie, CSO of Plethora, commented; 'We are delighted that another
leading pharmaceutical company has selected PSD401 for use in their development
of treatments for sexual dysfunction. This second agreement demonstrates clearly
that PSD401 can be a valuable aid to clinical development within major
pharmaceutical companies and is a key component in our commercialisation of the
product.'

As well as working with pharmaceutical companies that utilise the product in
clinical development and marketing programmes for drugs for the treatment of PE,
PSD401 will ultimately be used by the urologists, andrologists, other relevant
specialists and primary care physicians who are responsible for the diagnosis
and management of the large PE patient population. For this purpose, Plethora
has obtained both European and US marketing approval for the device, which will
be marketed through its subsidiary, Timm Medical. The recent 510K approval for
marketing of the device should also expedite acceptance in the US as a front
line diagnostic system. In this context, many of the key sexual health opinion
leaders in the USA are to take delivery of PSD401s in Q1 2007

In the expanding sexual health market, PSD401 complements Plethora's therapeutic
product PSD502 for the treatment of PE which is about to enter phase III
clinical trials once on-going partnering discussions are finalised.


-Ends-

Definitely good news today, and that's one thing you can say about PLE, is that there is a steady trickle of good news and product updates.

A slightly muted response from the market, though - only 8,805 shares traded so far today, but I guess until the big deal comes through, this may be travelling below many poeples' radar.

PLE Bid: 198p Offer: 205p Change: 3.5

Navajo -good point
Todays news is great -they have stated that more large pharmas are to take delivery of PSD401 - means more product revenues -thats what we want to hear.
Notice they haven't stated the Pharmas name or deal amount -I wonder if its the same company who they will announce the deal for PSD502 with? interesting.

PSD401 is apparently due for many deliveries in Q1 2007.

BTW, Hondaman, since you asked me for tips: Just want to let you know I have been persuaded to join the GTL club. This is the ethanol producer - they have big plans for growth and will soon be producing far more than RVA, which currently has a bigger market cap. New plant due to start commercial production in early December; capacity will then double as they extend the plant over the following year or so, plus they want to build a further three plants. Shares Mag has tipped it consistently this year.

Prospects for growth look excellent, but please DYOR, etc.

Anyone think this company will produce a deal by Christmas?

The suspense is killing me.

RNS out on 4th Dec - I missed it because I was too busy watching SOLA, but it's more good press for PLE!

Plethora Solutions - Product Update - ErecAid
RNS Number:2428N
Plethora Solutions Holdings PLC
05 December 2006


PLETHORA SOLUTIONS HOLDINGS PLC

Product Update

Osbon ErecAid(R): Use of ErecAid after Radical Prostate Surgery reduces
incidence of penile shortening.

Plethora Solutions Holdings plc ('Plethora', AIM: PLE), the specialist developer
of products for the treatment and management of urological disorders, notes the
publication of new research that shows that regular use of the Osbon ErecAid(R)
product marketed through Plethora's US subsidiary, Timm Medical, can reduce the
incidence of penile shortening in men recovering from prostate cancer surgery; a
procedure known as radical prostatectomy ('RRP').

An estimated 235,000 American men will be diagnosed with prostate cancer in 2006
(1), of which approximately 25% will be treated by having their prostate
surgically removed via a radical prostatectomy. Consequent tissue and nerve
damage and scar formation can lead to temporary or sometimes permanent loss of
erectile function and changes in penile dimension. Penile shrinkage occurs in
more than two-thirds of men undergoing radical prostatectomy, with reductions in
length of more than 1cm reported in almost half of men three months after
surgery(2),(3)

In a paper entitled 'Preservation of Penile Length After Radical Prostatectomy
(RRP): Early Intervention With a Vacuum Erection Device (VED)' presented at the
7th Annual Society of Urologic Oncology on December 1, 2006, Dr. Bruce Dalkin
reported that of the 28 men recovering from radical prostatectomy who made daily
use of the Osbon ErecAid(R) vacuum system, only one experienced a reduction in
penile length greater than 1cm. Of the four patients who did not make daily use
of the vacuum system, three experienced a reduction in penile length of more
than 1cm. The incidence of penile shrinkage in the experimental group of 3.5%
compared favorably to 48% incidence of penile shortening after RRP reported in
historical controls(2).

The study concludes that '...early intervention with VED should be recommended
in all potent men undergoing nerve-sparing RRP to preserve penile length.'


Dr Steven Powell, Plethora CEO, commented:

'The Osbon ErecAid(R) is frequently prescribed for patients for whom oral drugs
are ineffective treatments for erectile dysfunction. This new research
highlights the potential for the ErecAid(R) device to play a significant role in
minimising the impact of radical prostate surgery on a patient's quality of
life.'

--------------------------
(1) American Cancer Society 2006

(2) Munding MD, Wessells HB, Dalkin BL.Pilot study of changes in stretched
penile length 3 months after radical retropubic prostatectomy. Urology 2001;58:
567-93

(3) Savoie M, Kim SS, Soloway MS.A prospective study measuring penile length in
men treated with radical prostatectomy for prostate cancer. J Urol2003; 169 :
1462-44

-Ends-

chart is far from encouraging ..... on that basis, i would not be a buyer

It's the potential for a Phse III trials deal and/or takeover that makes this one appealing.

You might not like the shares, but are you able to provide a product review?? ;o)

nope .... never even heard of the company

:o)